摘要
目的观察黄葵胶囊联合ACEI及ARB治疗早期糖尿病肾病（DN）的有效性及安全性。方法选取本科2014年1-7月被诊断为早期DN的患者60例,随机分为两组,每组30例。在控制血糖的基础上,对照组给予依那普利、厄贝沙坦治疗,观察组在对照组基础上加用黄葵胶囊治疗。观察两组治疗后24 h尿蛋白排泄率（UAER）、血肌酐（SCr）、血尿素氮（BUN）、血糖、血压等的变化及用药后不良反应。结果随着治疗时间延长,两组UAER、SCr及BUN水平逐渐下降,观察组UAER、SCr及BUN较对照组低,差异有统计学意义（P〈0.05）;观察组血糖和血压各指标水平均低于对照组,差异有统计学意义（P〈0.05）;观察组出现2例不良反应,对照组未出现不良反应,差异无统计学意义（P〉0.05）。结论黄葵胶囊联合ACEI及ARB治疗早期DN是一种安全、有效的治疗方案。
Objective To observe the efficacy and safety of Abelmoschus moschatus capsule combined with ACEI and ARB on the urinary albumin excretion rate of early stage diabetic nephropathy （DN）. Methods 60 patients with early stage DN were randomly divided into two groups,with 30 cases in each group.Based on treatment of controlling blood glucose,the control group was given enalapril and irbesartan,the observation group was given A belmoschus moschatus capsule based on the treatment of control group.The urinary protein excretion rate（UAER）of 24 h,serum creatinine（SCr）, blood urea nitrogen（BUN） and blood glucose,blood pressure,and adverse reactions between two groups was observed re- spectively after treatment. Results With the treatment time prolonged,UAER,SCr and BUN of observation group was lower than that of control group respectively,with statistical difference （P〈0.05）.The blood glucose and blood pressure of observation group was lower than that of control group respectively,with statistical difference（P〈0.05）.There were 2 cases in observation group,no case in control group with adverse reactions,with no statistical differenc between two groups （P〉0.05）. Conclusion Abelmoschus moschatus capsule combined with ACEI and ARB in the treatment of early stage diabetic nephropathv is a safe,effective treatment scheme.
出处
《中国当代医药》
2015年第21期67-69,72,共4页
China Modern Medicine
基金
广东省云浮市科技计划项目(WS1320)
关键词
黄葵胶囊
血管紧张素转化酶抑制剂
血管紧张素Ⅱ受体拮抗剂
糖尿病肾病
Abelmoschus moschatus Capsule
Angiotensin converting enzyme inhibitors
Angiotensin Ⅱ receptor antagonist
Diabetic nephropathy
